Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SHUTTERSTOCK, INC.

(SSTK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

ViiV - FORTY YEARS ON FROM THE START OF THE HIV EPIDEMIC, NEW DATA REVEALS PEOPLE LIVING WITH HIV FACE OUTDATED ATTITUDES AND ONGOING DISCRIMINATION

12/02/2021 | 08:27am EST

London - Pervasive stigma and prejudice towards people living with HIV continues to persist, according to a new international survey released on World AIDS Day. Funded by ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline Plc ('GSK'), with Pfizer Inc. and Shionogi Limited as shareholders, the survey uncovers outdated attitudes and inherent bias amongst the general public towards people living with HIV. An overwhelming majority (88%) of respondents believe there are still negative perceptions towards people living with HIV, even though it can now be effectively managed with antiretroviral (ARV) medication. Concerningly, almost a third (30%) of people surveyed incorrectly believe HIV can be transmitted through kissing.

The survey, conducted online by The Harris Poll, surveyed 5,047 adults across four countries, Australia, Portugal, United Kingdom and United States. Data revealed that over three quarters (76%) of adults who responded are unaware that a person living with HIV who is taking effective treatment cannot pass HIV on to their sexual partners due to the virus being at a level that is undetectable in their blood.1 In recent years, an overwhelming body of clinical evidence has firmly established the Undetectable = Untransmittable (U=U) concept as scientifically sound, yet outdated misconceptions still exist.

This survey reinforces the importance of anti-stigma campaigns such as HIV in View, a collaboration between ViiV Healthcare and Shutterstock Studios to establish the largest online photo library of people living with HIV. HIV in View features empowering images that authentically portray the reality of living with HIV today. Far from reflecting the fear once associated with HIV, the gallery is filled with inspiring examples of just how much things have changed for many people living with HIV.

Commenting on the survey results, Silvia Petretti, CEO of Positively UK - a peer led charity which aims to improve health and quality of life for people with HIV - and participant in the photography collaboration said: 'Over the past four decades we've seen incredible progress in the HIV response yet, as this new survey clearly demonstrates, there are still many misconceptions around HIV. I am proud to have taken part in the HIV in View photography project, to show that people living with HIV can live fulfilling, healthy lives. I hope HIV in View helps people to understand the reality of living with HIV and removes HIV-related prejudice seen in the survey results.'

'The HIV community has made tremendous strides in tackling stigma and bias faced by people living with HIV, yet it is alarming to see the level of misunderstanding and inherent bias uncovered by this new survey,' says Deborah Waterhouse, Chief Executive Officer, ViiV Healthcare. 'We often hear from the HIV community that interactions with friends, family, the general public and even healthcare providers sometimes feel fractured due to misinformation, misconceptions and the inherent bias held towards people living with HIV. Our hope is that through anti-stigma campaigns such as HIV in View, we can change the way the world views HIV so that one day, we can finally dismantle pervasive stigma for good.'

About the survey

This survey was conducted online by The Harris Poll on behalf of ViiV Healthcare from October 13-18, 2021 among 5,047 adults ages 18 and older across 4 countries (2,036 adults in U.S., 1,012 adults in UK, 1,005 adults in Australia, 1,004 adults in Portugal). This online survey is not based on a probability sample and therefore no estimate of theoretical sampling error can be calculated. For complete survey methodology, including weighting variables and subgroup sample sizes, please contact Kate Senter, Global Corporate and Internal Communications Director at ViiV Healthcare kate.x.senter@viivhealthcare.com.

Notes to editor

The HIV in View collection is available for free under Shutterstock's standard license to use in projects, campaigns and communications. Users who require the enhanced license will be charged the higher license fee, of which 100% of the proceeds will be donated to (RED), a non-profit organisation helping fund the fight to end AIDS, at the discretion of Shutterstock.

About Shutterstock

Shutterstock, Inc. (NYSE: SSTK), is a leading global creative platform offering full-service solutions, high-quality content, and applications for brands, businesses and media companies. Directly and through its group subsidiaries, Shutterstock's comprehensive collection includes high-quality licensed photographs, vectors, illustrations, videos, 3D models and music. Working with its growing community of over 1.9 million contributors, Shutterstock adds hundreds of thousands of images each week, and currently has more than 390 million images and more than 23 million video clips available.

Headquartered in New York City, Shutterstock has offices around the world and customers in more than 150 countries. The Company also owns PicMonkey, a leading online graphic design and image editing platform; Offset, a high-end image collection; Shutterstock Studios, an end-to-end custom creative shop; PremiumBeat, a curated royalty-free music library; Shutterstock Editorial, a premier source of editorial images and videos for the world's media; TurboSquid, a leading 3D content marketplace; Amper Music, an AI-driven music platform; and Bigstock, a value-oriented stock media offering.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of becoming infected with HIV. Shionogi joined as shareholders in October 2012. The company's aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

About GSK

GSK is a science-led global healthcare company.

Contact:

ViiV Healthcare Media

Kate Senter

Global Corporate and Internal Communications

Director

E: kate.x.senter@viivhealthcare.com

Madison Goring

Communications and Government Affairs Associate

E: madison.x.goring@gsk.com

Media

Tim Foley

London

T: +44 (0) 20 8047 5502

London

Madeleine Breckon

T: +44 (0) 20 8047 5502

Philadelphia

Kristen Neese

T: +1 804 217 8147

Washington DC

Kathleen Quinn +1 202 603 5003

Analyst/Investor

London

Nick Stone

T: +44 (0) 7717 618834

London

James Dodwell

T: +44 (0) 20 8047 2406)

London

Mick Readey

T: +44 (0) 7990 339653

Philadelphia

Jeff McLaughlin

T: +1 215 751 7002

Philadelphia

Frannie DeFranco

T: +1 215 751 4855

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's Q3 Results and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

No. 3888792

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -1.23% 1660.4 Delayed Quote.3.39%
PFIZER, INC. 1.80% 54.33 Delayed Quote.-7.99%
SHUTTERSTOCK, INC. 1.11% 90.04 Delayed Quote.-19.69%
All news about SHUTTERSTOCK, INC.
01/27Shutterstock Earns Perfect Score in Human Rights Campaign's 2022 Corporate Equality Ind..
PR
01/25Shutterstock Raises Quarterly Dividend by About 14% to $0.24 Per Share; Payable March 1..
MT
01/25SHUTTERSTOCK : Increases Quarterly Dividend by 14% to $0.24 per share - Form 8-K
PU
01/25SHUTTERSTOCK, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
01/25Shutterstock Increases Quarterly Dividend by 14% to $0.24 per share
PR
01/25Shutterstock Declares Cash Dividend, Payable on March 17, 2022
CI
01/19Shutterstock Predicts Top Creative Trends For 2022
PR
01/14Shutterstock To Report Fourth Quarter 2021 Earnings Results on February 10, 2022
PR
01/13INSIDER SELL : Shutterstock
MT
01/10INSIDER SELL : Shutterstock
MT
More news
Analyst Recommendations on SHUTTERSTOCK, INC.
More recommendations
Financials (USD)
Sales 2021 770 M - -
Net income 2021 83,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 40,1x
Yield 2021 0,91%
Capitalization 3 316 M 3 316 M -
Capi. / Sales 2021 4,31x
Capi. / Sales 2022 4,01x
Nbr of Employees 967
Free-Float 61,8%
Chart SHUTTERSTOCK, INC.
Duration : Period :
Shutterstock, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHUTTERSTOCK, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 90,04 $
Average target price 134,75 $
Spread / Average Target 49,7%
EPS Revisions
Managers and Directors
Stan Pavlovsky Chief Executive Officer & Director
Jarrod Yahes Chief Financial Officer
Jonathan Evan Oringer Executive Chairman
Peter Silvio Senior VP, Head-Engineering & Architecture
Thomas R. Evans Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SHUTTERSTOCK, INC.-19.69%3 279
TENCENT HOLDINGS LIMITED0.70%566 508
PROSUS N.V.-4.12%200 626
NETFLIX, INC.-36.20%171 290
AIRBNB, INC.-14.25%86 671
UBER TECHNOLOGIES, INC.-16.03%66 139